Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy

Daniela Paola Roggeri, Alessandro Roggeri ProCure Solutions, Nembro, Bergamo, Italy Purpose: Hepatic encephalopathy (HE) is associated with a reduced survival, an increased risk of hospitalization for recurrences, and a reduced health-related quality of life. The purpose of the present econ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roggeri DP, Roggeri A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	hepatic encephalopathy costs hospitalisations budget impact Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/0221b76cd3d14738b2da70f91fdfe6d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0221b76cd3d14738b2da70f91fdfe6d1
record_format	dspace
spelling	oai:doaj.org-article:0221b76cd3d14738b2da70f91fdfe6d12021-12-02T02:59:36ZEconomic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy1179-1535https://doaj.org/article/0221b76cd3d14738b2da70f91fdfe6d12017-09-01T00:00:00Zhttps://www.dovepress.com/economic-impact-of-the-use-of-rifaximin-550-mg-twice-daily-for-the-tre-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Daniela Paola Roggeri, Alessandro Roggeri ProCure Solutions, Nembro, Bergamo, Italy Purpose: Hepatic encephalopathy (HE) is associated with a reduced survival, an increased risk of hospitalization for recurrences, and a reduced health-related quality of life. The purpose of the present economic analysis was to evaluate the impact on the Italian National Health Service (INHS) expenditure of the treatment with rifaximin 550 mg twice daily (Tixteller®/Tixtar®) for the reduction of the recurrences of overt HE, with respect to the current treatment approach. Patients and methods: Costs associated with patients treated with rifaximin 550 mg twice daily were estimated considering the reduction in hospitalizations for HE recurrences revealed by registrative clinical trial (−50%) applied to the hospitalization rate (42.5%) emerging from an Italian observational real-world study; costs associated with patients not treated with rifaximin were estimated based on the hospitalization rate, resulting from the same Italian observational study. Sensitivity analyses considering possible different discount levels to INHS structures for rifaximin were performed. The INHS perspective for a period of 3 years was considered. Results: The treatment with rifaximin 550 mg twice daily, although increasing drug costs, is associated with a reduction in hospitalizations for HE recurrences that leads to an overall reduction of total costs charged to INHS, which could be estimated, based on the forecasted uptake of the treatment, at about €130,000 in the first year, reaching ~€260,000 in the third year. Considering a possible discount for rifaximin 550 mg to INHS structure of 20%, the total saving at the third year accounts for ~€3,000,000. Moreover, a relevant reduction in the number of hospitalizations and bed days is associated with rifaximin treatment. Conclusion: The treatment with rifaximin 550 mg twice daily, even if associated with an increase in drug expenditure, results in a reduction in total health care costs charged to INHS due to a reduction in hospitalizations for HE recurrences. Keywords: overt hepatic encephalopathy recurrences, health care expenditure, costs, hospitalizations, budget impactRoggeri DPRoggeri ADove Medical Pressarticlehepatic encephalopathycostshospitalisationsbudget impactDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 9, Pp 37-43 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatic encephalopathy costs hospitalisations budget impact Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	hepatic encephalopathy costs hospitalisations budget impact Diseases of the digestive system. Gastroenterology RC799-869 Roggeri DP Roggeri A Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
description	Daniela Paola Roggeri, Alessandro Roggeri ProCure Solutions, Nembro, Bergamo, Italy Purpose: Hepatic encephalopathy (HE) is associated with a reduced survival, an increased risk of hospitalization for recurrences, and a reduced health-related quality of life. The purpose of the present economic analysis was to evaluate the impact on the Italian National Health Service (INHS) expenditure of the treatment with rifaximin 550 mg twice daily (Tixteller®/Tixtar®) for the reduction of the recurrences of overt HE, with respect to the current treatment approach. Patients and methods: Costs associated with patients treated with rifaximin 550 mg twice daily were estimated considering the reduction in hospitalizations for HE recurrences revealed by registrative clinical trial (−50%) applied to the hospitalization rate (42.5%) emerging from an Italian observational real-world study; costs associated with patients not treated with rifaximin were estimated based on the hospitalization rate, resulting from the same Italian observational study. Sensitivity analyses considering possible different discount levels to INHS structures for rifaximin were performed. The INHS perspective for a period of 3 years was considered. Results: The treatment with rifaximin 550 mg twice daily, although increasing drug costs, is associated with a reduction in hospitalizations for HE recurrences that leads to an overall reduction of total costs charged to INHS, which could be estimated, based on the forecasted uptake of the treatment, at about €130,000 in the first year, reaching ~€260,000 in the third year. Considering a possible discount for rifaximin 550 mg to INHS structure of 20%, the total saving at the third year accounts for ~€3,000,000. Moreover, a relevant reduction in the number of hospitalizations and bed days is associated with rifaximin treatment. Conclusion: The treatment with rifaximin 550 mg twice daily, even if associated with an increase in drug expenditure, results in a reduction in total health care costs charged to INHS due to a reduction in hospitalizations for HE recurrences. Keywords: overt hepatic encephalopathy recurrences, health care expenditure, costs, hospitalizations, budget impact
format	article
author	Roggeri DP Roggeri A
author_facet	Roggeri DP Roggeri A
author_sort	Roggeri DP
title	Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
title_short	Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
title_full	Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
title_fullStr	Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
title_full_unstemmed	Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
title_sort	economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in italy
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/0221b76cd3d14738b2da70f91fdfe6d1
work_keys_str_mv	AT roggeridp economicimpactoftheuseofrifaximin550mgtwicedailyforthetreatmentofoverthepaticencephalopathyinitaly AT roggeria economicimpactoftheuseofrifaximin550mgtwicedailyforthetreatmentofoverthepaticencephalopathyinitaly
_version_	1718401959603470336

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy

Ejemplares similares